PROVEN RESULTS IN ADVANCED BREAST CANCER
Why is PERJETA-based treatment used in HER2+ metastatic breast
If you have been diagnosed with metastatic HER2-positive (HER2+)
breast cancer, an aggressive form of cancer, it is important to
determine a treatment path quickly. PERJETA and Herceptin®
(trastuzumab) combination-based treatment may be an appropriate option
for patients with HER2+ advanced breast cancer that
- has spread to other parts of the body (metastatic), and
- has NOT been treated with traditional chemotherapy or
HER2-targeted treatments before
PERJETA in combination with Herceptin and docetaxel is proven to
help control cancer growth
A clinical study called CLEOPATRA studied efficacy and safety in 808
patients who were given PERJETA plus Herceptin and docetaxel. Results
from this trial showed that PERJETA is proven to help control growth
of HER2+ metastatic breast cancer.
PERJETA helped patients live longer
On average, patients who were given PERJETA, Herceptin, and docetaxel lived 15.7 months longer than patients given only Herceptin and docetaxel (56.5 months compared to 40.8 months).
PERJETA is proven to shrink tumors
- 80% of patients who were given the PERJETA combination had
their tumors shrink, compared with 69% of patients receiving
Herceptin and docetaxel alone
- Patients who had their
tumors shrink maintained this response, on average, for 62% longer
on the PERJETA combination compared with patients receiving only
Herceptin and docetaxel (20.2 months vs 12.5 months)
Side effects may occur with PERJETA
PERJETA is given together with Herceptin and docetaxel. Side effects
can occur with this treatment plan. Not all patients have serious side
effects; however, side effects with PERJETA-based treatment are
common. It is important to know what side effects may happen and what
symptoms you should watch for.
What are the most serious side effects of PERJETA?
Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.
PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).
What are other possible serious side effects of PERJETA?
PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA. Possible serious side effects of PERJETA include infusion-related reactions and severe allergic reactions (hypersensitivity reactions/anaphylaxis).
In the CLEOPATRA study, the most common side effects of PERJETA +
Herceptin + docetaxel were
- Hair loss
- Low levels
of white blood cells with or without a fever
- Feeling tired
- Damage to the nerves (numbness, tingling, pain in
If your doctor changes your treatment plan, you may see a change in
the side effects.
Patients in the study had less-frequent side effects when they
stopped receiving docetaxel. After stopping docetaxel, all side
effects in the PERJETA combination group happened in less than 10% of
patients, except for diarrhea, a cold, rash, headache, and feeling
Always report side effects to your healthcare team at any point in
You are encouraged to report side effects to Genentech and the FDA.
You may contact Genentech by calling 1-888-835-2555. You may contact
the FDA by visiting www.fda.gov/medwatch or calling